Editas Medicine (EDIT) Liabilities and Shareholders Equity (2015 - 2025)

Editas Medicine (EDIT) has reported Liabilities and Shareholders Equity for 11 consecutive years, with $186.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 45.39% year-over-year to $186.5 million; the TTM figure through Dec 2025 stood at $862.5 million (down 42.28% YoY), while the FY2025 annual figure was $186.5 million, down 45.39% from the prior year.
• Liabilities and Shareholders Equity retreated to $186.5 million in Q4 2025 per EDIT's latest filing, from $201.8 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $780.3 million in Q1 2021 and bottomed at $186.5 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $477.3 million across 5 years, with a median of $501.9 million in 2023.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity surged 67.18% — and 2025, when it tumbled 45.39%.
• Editas Medicine's Liabilities and Shareholders Equity stood at $677.5 million in 2021, then retreated by 24.08% to $514.3 million in 2022, then declined by 2.95% to $499.2 million in 2023, then sank by 31.57% to $341.6 million in 2024, then sank by 45.39% to $186.5 million in 2025.
• Business Quant data shows EDIT's Liabilities and Shareholders Equity at $186.5 million in Q4 2025, $201.8 million in Q3 2025, and $210.6 million in Q2 2025.